Clinical trials · Michigan
Down Syndrome clinical trials in Michigan
We’re tracking 92 recruiting down syndrome studies with a site in Michigan — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Michigan
- NCT07558265Recruiting
Comparing breathing support methods in the emergency department
This study tests two common ways to help people who are having trouble breathing in the emergency room: a face mask that pushes air into the lungs (non-invasive positive pressure ventilation) or high-flow oxygen through small tubes in the nose (high-flow nasal oxygen). The goal is to find which method works better to avoid needing a breathing tube.
Ann Arbor, MichiganAges 18 years+ - NCT07494968Recruiting
Finding ways to track diet compliance in IBS patients
This study looks for signs in your body—like breath and blood tests—that can show how well you are following a special diet for IBS. It aims to find better ways to track diet compliance, which could help make dietary treatments more effective.
Ann Arbor, MichiganAges 18–65 - NCT07444567RecruitingPhase 3
Continuing benralizumab treatment after a previous study
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
Ann Arbor, MichiganAges 6 years+ - NCT07296991Recruiting
Virtual reality exercise study for sedentary adults
This study tests if watching a virtual reality (VR) exercise video can give some of the same health benefits as real exercise. It might help people who are not active now and have slightly high blood sugar or blood pressure.
Detroit, MichiganAges 25–40 - NCT07220187RecruitingPhase 3
Adding pirtobrutinib to usual treatment for newly diagnosed Richter transformation
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
Brighton, MichiganAges 18 years+ - NCT06927739RecruitingPhase 2
Orticumab for heart artery inflammation after a heart attack
This trial tests a drug called orticumab to see if it can reduce inflammation in the arteries of the heart after a heart attack. It may help prevent future heart problems.
Midland, MichiganAges 18 years+ - NCT02852031Recruiting
Care program for newborns needing the Norwood procedure
This trial focuses on improving care for babies born with certain complex heart conditions where only one pumping chamber works. It is meant for babies (including unborn babies) who are planned to have the Norwood procedure, which is a common early surgery.
Ann Arbor, MichiganAges Up to 1.3 years - NCT06898996Recruiting
Stool test study for Lynch syndrome colon screening
This trial tests a new stool-based test (FIT) to see if it can help find colon cancer early in people with Lynch syndrome. You will collect stool samples at home and complete surveys before your regular colonoscopy.
Ann Arbor, MichiganAges 20–80 - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Detroit, MichiganAges 18–66 - NCT06430528Recruiting
Osilodrostat and steroid replacement for Cushing syndrome
This trial tests a new approach, called 'block-and-replace', for treating Cushing syndrome. You will take osilodrostat to lower high cortisol levels, along with a glucocorticoid (a steroid) to replace what your body needs. This study may help control the disease if surgery hasn't worked or isn't an option.
Ann Arbor, MichiganAges 18–75 - NCT06428019RecruitingPhase 3
Comparing drug combinations for untreated CLL or SLL
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Detroit, MichiganAges 18 years+ - NCT05412927Recruiting
Heart device follow-up study for high-risk heart patients
This study monitors how well the AngelMed Guardian® System works after it has already been implanted. It focuses on people at higher risk of heart events, including those with diabetes or kidney problems.
Grand Rapids, MichiganAges 21 years+ - NCT06150599Recruiting
Sacral nerve stimulation for chronic pelvic pain
This study tests whether a pacemaker-like device placed near the tailbone can reduce long-term pelvic pain in women who haven't gotten relief from other treatments.
Royal Oak, MichiganAges 22–70 - NCT06112418Recruiting
Personalized vs standard care to prevent heart attacks
This trial compares two ways to prevent heart attacks and strokes: one uses a special heart CT scan to guide care, the other uses standard risk factors like blood pressure and cholesterol. You may be eligible if you are older (men over 55, women over 65) and have diabetes, prediabetes, or metabolic syndrome.
Ypsilanti, MichiganAges 55 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Ann Arbor, MichiganAges Any age - NCT05956041RecruitingPhase 2
Pembrolizumab and mogamulizumab for advanced relapsed skin lymphoma
This Phase 2 trial studies two immune medicines (pembrolizumab and mogamulizumab) for people with advanced cutaneous T-cell lymphoma that has come back or did not respond to prior treatment. It aims to control the lymphoma and improve outcomes when the disease is hard to treat.
Ann Arbor, MichiganAges 18 years+ - NCT05918861RecruitingPhase 3
Tested heart-risk drug for people with recent heart-attack genetics
This trial studies whether dalcetrapib can lower future heart and blood-vessel risk in people who recently had an ACS (acute coronary syndrome, often a heart attack or unstable chest pain) and have a specific genetic marker. It may help people like you by targeting a risk pathway related to that genetic background.
Bay City, MichiganAges 45 years+ - NCT05922761RecruitingPhase 2
Belumosudil for lung scar prevention or treatment after transplant
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
Ann Arbor, MichiganAges 18 years+ - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Ann Arbor, MichiganAges 1 month–21 years - NCT05806801Recruiting
Study how weight loss changes the body with or without exercise
This study looks at how your metabolism (how your body uses energy and controls blood sugar/fats) changes during weight loss, comparing weight loss alone versus weight loss plus exercise. It may help researchers understand what body changes happen with different approaches and why.
Ann Arbor, MichiganAges 18–40 - NCT05701917Recruiting
Clot-busting device versus blood thinners for leg clot
This study compares a clot-removal device (ClotTriever) plus standard care versus standard blood thinners alone for a deep vein clot in the leg. It aims to see which approach better improves leg symptoms and outcomes.
Bay City, MichiganAges 18 years+ - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Ann Arbor, MichiganAges 18–65 - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Ann Arbor, MichiganAges 18 years+ - NCT05527652Recruiting
Breathing tube device to help blocked upper airways in children
This study tests a self-supporting breathing tube placed through the nose during sleep to reduce upper airway blockage and improve breathing in children. It may help children who have sleep apnea symptoms, especially after tonsil/adenoid treatment or when tonsil removal isn’t possible.
Ann Arbor, MichiganAges 3–21
Down Syndrome trials by city in Michigan
Where these studies are running in Michigan
Institutions with a site for the recruiting down syndrome studies listed above.
- University of Michigan · 6 studies
- Henry Ford Health · 3 studies
- Karmanos Cancer Institute · 2 studies
- Research Site · 2 studies
- Trinity Health Brighton · 2 studies
- Trinity Health IHA Medical Group Hematology Oncology - Canton · 2 studies
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital · 2 studies
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus · 2 studies
What taking part in a down syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Down Syndrome trials in other states
Common questions
- Are there down syndrome clinical trials in Michigan?
- Yes. We're currently tracking 92 recruiting down syndrome studies with a site in Michigan, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a down syndrome study in Michigan?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Michigan to take part?
- Not necessarily. These studies have a site in Michigan, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a down syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New down syndrome studies open in Michigan regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.